GH1 and cleidocranial dysplasia 1: Understanding the relationship between the mutations in RUNX2 and CCD-associated phenotypes, including the final height of patients or the number of supernumerary teeth, may enable the early initiation of effective treatments, such as therapy with recombinant human growth hormone at an appropriate stage.